{"id":"NCT04233918","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia","officialTitle":"A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-29","primaryCompletion":"2022-01-31","completion":"2023-05-30","firstPosted":"2020-01-18","resultsPosted":"2023-06-07","lastUpdate":"2024-07-16"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Homozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Evinacumab","otherNames":["REGN1500","Evkeezaâ„¢"]}],"arms":[{"label":"Evinacumab","type":"EXPERIMENTAL"}],"summary":"The primary objective for Part A of the study is to assess the pharmacokinetics (PK) of evinacumab in pediatric patients with homozygous familial hypercholesterolemia (HoFH).\n\nThe primary objective for Part B of the study is to demonstrate a reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab in pediatric (5 to 11 years of age) patients with HoFH.\n\nThe secondary objective for Part A of the study is to evaluate the safety and tolerability of evinacumab administered intravenous (IV) in pediatric patients with HoFH.\n\nThe secondary objectives for Part B of the study are:\n\n* To evaluate the effect of evinacumab on other lipid parameters (ie, apolipoprotein B (Apo B), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), lipoprotein a \\[Lp(a)\\]) in pediatric patients with HoFH\n* To evaluate the safety and tolerability of evinacumab administered IV in pediatric patients with HoFH\n* To assess the PK of evinacumab in pediatric patients with HoFH\n* To assess the immunogenicity of evinacumab in pediatric patients with HoFH over time\n* To evaluate patient efficacy by mutation status","primaryOutcome":{"measure":"Part A: Maximum Observed Serum Concentration (Cmax) of Evinacumab","timeFrame":"At day 12","effectByArm":[{"arm":"Part A: Evinacumab 15mg/Kg IV","deltaMin":238,"sd":90.8}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["United States","Australia","Austria","Netherlands","Taiwan","Ukraine"]},"refs":{"pmids":["37860863"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["COVID-19","Oropharyngeal pain","Headache","Vomiting","Cough"]}}